Abstract
Evaluation of: Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br. J. Cancer 95(11), 1459–1466 (2006).Human papillomavirus (HPV) infection causes genital warts and cervical cancers. A number of preventive HPV vaccines have been developed. Follow-up of patients who were enrolled in initial efficacy trials of these vaccines is ongoing. Such trials have proven HPV vaccines to be effective in preventing persistent infection and cervical disease; however, long-term safety, efficacy and immunogenicity can only be ascertained by longer-term follow-up. At 5 years’ follow-up, the prophylactic quadrivalent HPV vaccine targeting HPV 6/11/16/18 demonstrates an excellent safety profile and continues to prevent persistent infection and disease. The need for booster immunizations continues to be under review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
